By Karen Roman Imviva Biotech said it has FDA authorization for its Investigational Device Exemption application to use ...
Parabilis Medicines is ambitious, but it has Regeneron on its side already.
The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...
Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...
Alvotech (ALVO) announced an amendment to its existing credit agreement, securing a new term loan facility of up to $75M. The financing was led by long-term partner GoldenTree Asset Management LP ...
Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...
Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...
It has been a banner year for biotech buyouts, and these are two of the prime targets.
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...
IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results